Rapamycin (Sirolimus)

Licensed by Pfizer Catalog No.S1039 Synonyms: AY 22989，NSC-2260804

Rapamycin (Sirolimus) Chemical Structure

Molecular Weight(MW): 914.18

Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.

Size Price Stock Quantity  
In DMSO USD 306 In stock
USD 70 In stock
USD 270 In stock
USD 670 In stock
Bulk Discount
Bulk Inquiry

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 932 Publications

Purity & Quality Control

Choose Selective mTOR Inhibitors

Biological Activity

Description Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.
Targets
mTOR [1]
(HEK293 cells)
~0.1 nM
In vitro

Rapamycin inhibits endogenous mTOR activity in HEK293 cells with IC50 of ~0.1 nM, more potently than iRap and AP21967 with IC50 of ~5 nM and ~10 nM, respectively. [1] In Saccharomyces cerevisiae, Rapamycin treatment induces a severe G1/S cell cycle arrest and inhibition of translation initiation to levels below 20% of control. [2] Rapamycin significantly inhibits the cell viability of T98G and U87-MG in a dose-dependent manner with IC50 of 2 nM and 1 μM, respectively, while displaying little activity against U373-MG cells with IC50 of >25 μM despite the similar extent of the inhibition of mTOR signaling. Rapamycin (100 nM) induces G1 arrest and autophagy but not apoptosis in Rapamycin-sensitive U87-MG and T98G cells by inhibiting the function of mTOR. [3]
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HT-29 MX;DfZRwfG:6aXOgRZN{[Xl? M1vKOlExKG6P M4nldVczKGh? NIrPVYNFVVOR M{LhOHBwfGWwdHnheIV{KGOjbYD0c5Rp\WOrbj3pcoR2[2WmIHP5eI91d3irY3n0fS=> NX\veFB[OjR7MEC4O|M>
HT-29 Mk[zR5l1d3SxeHnjJGF{e2G7 NWTJXHd3OTBibl2= NIL4RXM4OiCq NHHXWJhFVVOR NWG4[XFlWG:2ZX70bYF1\XNiZHnnbZRwgGmwLXnu[JVk\WRiY4n0c5RwgGmlaYT5 M1HPUlI1QTByOEez
HT-29 NHXMWoZEgXSxdH;4bYMhSXO|YYm= MW[xNEBvVQ>? MYm3NkBp MYTEUXNQ NVi3TolXWG:2ZX70bYF1\XNiNT3mcJVwem:3cnHjbYwucW6mdXPl[EBkgXSxdH;4bYNqfHl? MlvONlQ6ODB6N{O=
PC3 Mk\LT4lv[XOnIFHzd4F6 MkjJNVAxKG6P MUOxJIg> NETlVI1FVVOR NHzDcJRRd3SnboTsfUBqdmirYnn0d{BuXE:ULX3l[IlifGWmIGO2JJBpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhRDFyIH7NMi=> NYTVbohtOjF7N{i2PFM>
PC3 M1XOWWtqdmG|ZTDBd5NigQ>? NFLBVHMyODBibl2= M1\JUlEhcA>? NVPxT|N3TE2VTx?= M3XaSmRw\XNibn;0JIlvcGmkaYSgcXRQWi2vZXTpZZRm\CCDa4SgdIhwe3Cqb4L5cIF1cW:w NFn1UpQzOTl5OE[4Ny=>
PC3 Ml21S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPUNU42KM7:TR?= NXjK[HprOSCq MV7EUXNQ MXrJcoR2[2W|IHHueIlxem:uaX\ldoF1cX[nIHHjeIl3cXS7IHHnZYlve3RiaIXtZY4hWEN|IHPlcIx{KHerdHigTWM2OCCxZjC8NVAhdk1? M4L0b|IyQTd6Nkiz
HEK293 MWTGeY5kfGmxbjDBd5NigQ>? NUfpT49KOTByIH7N MXy4JIg> M3qxdmROW09? NWKzSnA5UW6qaXLpeJMhXFCDLXnu[JVk\WRiZHXndoFl[XSrb36gc4YhWGSlZESge4l1cCCHQ{WwJI9nKDVyIH7N NX7FXXd7OjF3M{mzNFE>
BT-20 NX75SFVLU2mwYYPlJGF{e2G7 MkfmNlAh|ryP MXjEUXNQ MV3Ec4V{KG6xdDDpcohq[mm2IH3UU3JEOiCmZYDlcoRmdnRicFHrWEBUPDd|IIDoc5NxcG:{eXzheIlwdg>? MnTkNlE{PTN3NUG=
U937 NUjlV5Z6SW62aXLhZ5RmemmjbDDBd5NigQ>? MYO1NEDPxE1? NFv2UG41QCCq M3XuUGROW09? MXzJcoR2[2W|IHHueIlj[WO2ZYLpZYwh[WO2aY\peJkh[WejaX7zeEB4cWymIIT5dIUhVGWpaX;u[Yxt[SCybnX1cY9xcGmuYTDQbIlt[WSnbIDobYEuOSCMUkOyJIlvKFV7M{egZ4VtdHN? MoXHNlEyPDJzME[=
U937 M{jCNmFvfGmkYXP0[ZJq[WxiQYPzZZk> NFfJS4c2OCEQvF2= MoLLOFghcA>? NYXmWJBpTE2VTx?= MWPEc4V{KG6xdDDpcoR2[2ViYX70bYJi[3SncnnhcEBi[3Srdnn0fUBi\2GrboP0JG1KWCCycn;0[YlvNWSnZnnjbYVvfCCOZXfpc45mdGyjIIDu[ZVud3CqaXzhJGpTOzJvMjDpckBWQTN5IHPlcIx{ MorBNlEyPDJzME[=
U937 NXf6[pN4SW62aXLhZ5RmemmjbDDBd5NigQ>? M33v[|UxKM7:TR?= NIi0WHI1QCCq MkSySG1UVw>? NV\IOIROTG:nczDuc5QhcW6mdXPlJIFvfGmkYXP0[ZJq[WxiYXP0bZZqfHliYXfhbY5{fCCHc3Po[ZJq[2irYTDjc4xqKEiEMUCxJIlvKFV7M{egZ4VtdHN? M1j4c|IyOTR{MUC2
MCF-7 M3jEfmF2fG:yaHHnfUBCe3OjeR?= M3\yVlMxKG6P NEHsfJM1KGh? M4frd2ROW09? NHO5NoVKdmS3Y3XzJIF2fG:yaHHnfS=> NYLaO4FrOjByMkixN|Q>
U87MG NYLzUWM6U2mwYYPlJGF{e2G7 MV2xJO69VQ>? M{fCWFYhcA>? M13ubWROW09? M17VXHBwfGWwdHz5JIlvcGmkaYTzJI1VV1JvbXXkbYF1\WRiU{[gdIhwe3Cqb4L5cIF1cW:w MnLwNVk5PDh2MES=
U87MG M{DKVmtqdmG|ZTDBd5NigQ>? M4DWclEh|ryP NFX3fmk3KGh? Mn\NSG1UVw>? M2rJS3BwfGWwdHz5JIlvcGmkaYTzJFRGSlBzKGS3NEkheGixc4Doc5J6dGG2aX;u MX[xPVg1QDRyNB?=
U87MG MoLXT4lv[XOnIFHzd4F6 MWSxJO69VQ>? NXrlfHAxPiCq NV\w[GRjTE2VTx?= NF6yRoVFd2W|IH7veEBqdmirYnn0JI1VV1JvbXXkbYF1\WRiQXv0JJBpd3OyaH;yfYxifGmxbh?= NGHlbGIyQTh2OESwOC=>
U87MG NGnhNpBMcW6jc3WgRZN{[Xl? MnXPNUDPxE1? M3W4TVYhcA>? M4DzdmROW09? Mm\YSI9meyCwb4SgbY5pcWKrdDDQMVRGSlBzKGSzO{81PilicHjvd5Bpd3K7bHH0bY9v NF:5fooyQTh2OESwOC=>
COS7 cells expressing EGFP-HDQ74/rheb MkXKRZV1d3CqYXf5JGF{e2G7 NEHOcI0xNjJizszN NF7NdXczPCCq Mn32SG1UVw>? NWq3R3lWUW6mdXPld{BifXSxcHjh[5k> M{nPVlE5OzlzOUS5
COS7 cells expressing EGFP-LC3 Mo\nRZV1d3CqYXf5JGF{e2G7 M3S1TFAvOiEQvF2= NWjpZmM1OjRiaB?= MmfTSG1UVw>? NInkOHRKdmS3Y3XzJIF2fG:yaHHnfS=> Mk\BNVg{QTF7NEm=
H4 NHvBd4NHfW6ldHnvckBCe3OjeR?= NYizOIljOC5{IN88US=> M3TheFI1KGh? NUnNOmZNTE2VTx?= MV\JcoNz\WG|ZYOgeIhmKHKjdHnvJI9nKGyrZ3j0JINp[WmwIEOgd5VjfW6rdDCyJJRwKGyrZ3j0JINp[WmwIEOgd5VjfW6rdDCxJIlvKGi3bXHuJGg1KGOnbHzz NF7UOpgyQDB{NEW4OC=>
HeLa NHO0epJHfW6ldHnvckBCe3OjeR?= MVGxNFAhdk1? M17rN|M3KGh? NEDGeVZFVVOR MmKzTY5lfWOnczDGVmIhUzJyOUXQMEBVOjB7OFysJHczOTBzRjDteZRidnRvdXLpdZVqfGmwQzDpcpRmemGldHnvci=> M1XlZlE4PTZ|M{i1
HeLa NGrzWlBHfW6ldHnvckBCe3OjeR?= M2f2XFExOCCwTR?= NWSwZZBROzZiaB?= MVTEUXNQ M2n3Nmlv\HWlZYOgSnJDKFd{MUCxSkBufXSjboSteYJqeXWrdHnuR{BqdnSncnHjeIlwdg>? MYexO|U3OzN6NR?=
HeLa M1HoemZ2dmO2aX;uJGF{e2G7 NGD0cWMyODBibl2= MUmzOkBp NHn2XFRFVVOR MWHJcoR2[2W|IF\SRk1HU0KSIHPvcZBt\XhiaX70[ZJi[3Srb36= M37CS|E4PTZ|M{i1
SYF M3v4SWZ2dmO2aX;uJGF{e2G7 M3;mOFExOCCwTR?= NV;qU3Z1OjRiaB?= NFfiTmpFVVOR NX7ieZpNUW6mdXPld{BHWkJvRlvCVEBkd22ybHX4JIlvfGW{YXP0bY9v NV7oOWw6OTd3NkOzPFU>
SYF M1P0cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVu5ZVlqOTByIH7N NEPBOIkzPCCq NF;OTIdFVVOR MULJcoR2[2W|IHHueIlxem:uaX\ldoF1cX[nIHHjeIl3cXS7IHHnZYlve3RiU2nGJINmdGy| M3j4N|E4PTZ|M{i1
HEK293T MV\BcpRqfmm{YXygRZN{[Xl? MoL5NUBvVQ>? M2\jOVQh\A>? NWnIcIdCTE2VTx?= M4Dkemlv\HWlZYOgZY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTGlXOSCUNTD3bZRpKEWFNUCgc4YhOC5zIH7N MkCyNVc1QDV3MEG=
HEK293T NIi1T3NCdnSrdnnyZYwhSXO|YYm= M{jwVVEhdk1? MnnoOEBl NYjRXYpJTE2VTx?= NWjxSmdiUW6mdXPld{BidnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJUVZzIGi0JJdqfGhiRVO1NEBw\iByLkOgcm0> NX3rOINYOTd2OEW1NFE>
PBMC NHXjRZNHfW6ldHnvckBCe3OjeR?= MVKxJI5O MUixOEBl MV\EUXNQ NY\QfoJLWmWmdXPld{BES1J3IHTlcpNqfHl? NIj5[FgyPzR6NUWwNS=>
PBMC MXfGeY5kfGmxbjDBd5NigQ>? NVXBNohjOSCwTR?= MlrQNVQh\A>? MUnEUXNQ NYHB[5Q3TG:nczDuc5Qh[W[oZXP0JGNZS1J2IHTlcpNqfHl? M4DDVlE4PDh3NUCx
HEK293 cells MnzKT4lv[XOnIFHzd4F6 NFX6W|E2OCCwTR?= NEHxVG01PSCvaX6= MlPISG1UVw>? NX;CNpV2UW6qaXLpeJMhdVSRUjDrbY5ie2ViYXP0bZZqfHlid3n0bEBKSzVyIH;mJFAvOSCwTR?= M{eyUVE4OzVyOUWz
Drosophila melanogaster S2 cells transfected with N-luc and C-luc MVjGeY5kfGmxbjDBd5NigQ>? MmXYNVAxKG6P NIPYRVc1KGh? NF7QS2hFVVOR M332Wmlv\HWlZYOgcJVkcW[ncnHz[UBxem:2ZXnuJJRz[W6|LYPwcIlkcW6pIHnuJGRzd3OxcHjpcIEhdWWuYX7v[4F{fGW{IGOyJINmdGy|IITyZY5{\mWldHXkJJdqfGhiTj3seYMh[W6mIFOtcJVk MYexO|EzQDJ4Mh?=
Human mixed lymphocyte MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInBN5E2KG6P M4rsUGROW09? MlTQTWM2OD1zLk[gcm0v NIfNeHAyPjF6NUi2OS=>
Lewis rat lymph node cells MljzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3e5flUh|ryP NX[2OVQyTE2VTx?= NHv6elJKSzVyPUKuOkDPxE1? M3TadlE3OTh3OE[1
cells from the thymus of normal BALB/c mice M2j5c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\iNVAhdk1? MV23NkBp M17nVGROW09? M4XoXWlvcGmkaYTzJIx6dXCqb4Dyc4xq\mW{YYTpc44hMEyDRjmge4l1cCCLQ{WwJI9nKDNibl2= M4rxVVExODJzOUS4
MRK-nu-1 NW\3cIw3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTBwOES1JJBO MXXTRW5ITVJ?
OCUB-M NF\6[G1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrESIdKSzVyPUWuNlQheE1? MWHTRW5ITVJ?
SF539 NH3UUGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTFzLk[gdG0> M1;tT3NCVkeHUh?=
ES4 NE\pVIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\3TmlEPTB;MkGuOUBxVQ>? NXjjb|RXW0GQR1XS
RL95-2 NVfa[WNiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnMeFlKSzVyPUGwO{BxVQ>? M3P0d3NCVkeHUh?=
LC-2-ad MnTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTR{MzDwUS=> MnXMV2FPT0WU
Daudi MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTR|NDDwUS=> NVnm[2wxW0GQR1XS
NTERA-S-cl-D1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;DcWdNUUN3ME20OFMheE1? NIjiVpRUSU6JRWK=
OS-RC-2 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfwZXhKSzVyPU[1NkBxVQ>? NHS2T25USU6JRWK=
VA-ES-BJ MlHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHYWo0zUUN3ME23NlMheE1? M2rNb3NCVkeHUh?=
GR-ST MoP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljRTWM2OD16NE[gdG0> NFX2VXZUSU6JRWK=
SW872 NXz6NIdNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrQ[lVKSzVyPUi0OkBxVQ>? MlWxV2FPT0WU
NOS-1 M1XZRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXO0TWZpUUN3ME24O|EheE1? NWS1OHM4W0GQR1XS
MC116 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTl6NTDwUS=> MYnTRW5ITVJ?
NCI-H1355 NYnBV4tPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fnN2lEPTB;MT6wNUBvVQ>? NXP4OGk3W0GQR1XS
RPMI-8226 M{D1XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLnTG1KSzVyPUGuNVkhdk1? MkjCV2FPT0WU
TE-15 MnzTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTFwM{[gcm0> MnTTV2FPT0WU
Ramos-2G6-4C10 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DrOmlEPTB;MT60OkBvVQ>? MkTZV2FPT0WU
KU812 NWrzd2l1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHlc3dKSzVyPUKuNFEhdk1? MUnTRW5ITVJ?
EW-1 MnfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnsNIFKSzVyPUKuNVchdk1? NYDWOohmW0GQR1XS
KS-1 NHnBOJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGCzV4lKSzVyPUKuOFUhdk1? M3uwb3NCVkeHUh?=
SK-LMS-1 MoLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DYN2lEPTB;Mj60PUBvVQ>? M1H5UXNCVkeHUh?=
TGBC1TKB MlLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPFZYdKSzVyPUKuOlkhdk1? NIThPI9USU6JRWK=
TE-6 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTJwN{egcm0> NYDTR29LW0GQR1XS
ETK-1 MkjHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTzNnZKSzVyPUKuPFIhdk1? NH;TemRUSU6JRWK=
BE-13 NHTDRlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITvTXVKSzVyPUKuPVkhdk1? MoX3V2FPT0WU
A3-KAW MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nvfGlEPTB;Mj65PUBvVQ>? NUfnZXQ1W0GQR1XS
TE-10 M1;Je2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUf1NFJ{UUN3ME2zMlMhdk1? MlHiV2FPT0WU
DOHH-2 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvGS2dKSzVyPUOuN|Uhdk1? Mn7zV2FPT0WU
ES6 MmrBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDFTWM2OD1|LkSzJI5O M3ft[XNCVkeHUh?=
OPM-2 NELWR4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn30TWM2OD12LkG1JI5O NWX5dFdoW0GQR1XS
SH-4 M37tcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTRwM{Sgcm0> NFj1RVNUSU6JRWK=
NB13 M4\OTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TL[2lEPTB;ND6zOkBvVQ>? MYPTRW5ITVJ?
HUTU-80 NXf4eHpyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXQTWM2OD12LkSyJI5O MWrTRW5ITVJ?
CCRF-CEM NEiwWo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPodlN7UUN3ME20Mlk1KG6P MYrTRW5ITVJ?
TGBC24TKB M{Hp[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPj[JlKSzVyPUWuOVEhdk1? MmrqV2FPT0WU
697 NIK2bFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELlNVJKSzVyPU[uNlghdk1? NX\s[IVlW0GQR1XS
J-RT3-T3-5 M3vnVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nTO2lEPTB;Nj60OkBvVQ>? NXjLV|R7W0GQR1XS
KALS-1 MmfyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjZbpB3UUN3ME22MlU3KG6P NEnaNGdUSU6JRWK=
no-10 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnOTWM2OD15LkK5JI5O NY\IfWx4W0GQR1XS
SK-NEP-1 MlvhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXWZ4h7UUN3ME24Mlc6KG6P NFHFWW9USU6JRWK=
L-540 NXvUbVMzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDEWFBKSzVyPUGwMlQzKG6P NFzT[oFUSU6JRWK=
JiyoyeP-2003 Mn;sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLHTWM2OD1zMD65OEBvVQ>? NXf3eoVwW0GQR1XS
HH MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPqTWM2OD1zMT6zPUBvVQ>? MonPV2FPT0WU
SR MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPiTWM2OD1zMT60OUBvVQ>? MUfTRW5ITVJ?
QIMR-WIL NITVNY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TrNmlEPTB;MUGuPFUhdk1? NX:zZ2N[W0GQR1XS
A4-Fuk M2\u[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fHRWlEPTB;MUOuNVIhdk1? MYrTRW5ITVJ?
CESS M1LFUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfQRWJKSzVyPUGzMlE{KG6P MV3TRW5ITVJ?
KE-37 NYTSc4NiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\lTWM2OD1zNj6wO{BvVQ>? Mn;6V2FPT0WU
SK-UT-1 NHLVWIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHoTWM2OD1zNj64NUBvVQ>? NWniTpJxW0GQR1XS
SIG-M5 MkW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTF5LkK1JI5O NH75SVhUSU6JRWK=
HT NYnRWlVHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\He|VrUUN3ME2xO{43KG6P NUP1fY5RW0GQR1XS
DEL MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXKeGxKSzVyPUG3Mlk6KG6P NXfrOVJ{W0GQR1XS
SK-PN-DW M{fhfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWqwOXZKUUN3ME2yNE4zOyCwTR?= MV7TRW5ITVJ?
RPMI-8402 NHHLOIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nodmlEPTB;MkGuO|chdk1? NFTXTpdUSU6JRWK=
RPMI-6666 Mn3vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3[yNmlEPTB;MkSuOFIhdk1? NELSS25USU6JRWK=
NCI-H720 NHvmVoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXjRW1KSzVyPUK1MlQyKG6P MW\TRW5ITVJ?
EW-16 MnjNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXiTWM2OD1{Nj64O{BvVQ>? NFvROVFUSU6JRWK=
BL-70 M4nmVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rBZWlEPTB;MkiuN|ghdk1? NXjkb|duW0GQR1XS
SF126 MkHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTNyLkO4JI5O MV\TRW5ITVJ?
BC-1 NES5fmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvqVG9KSzVyPUOxMlI3KG6P NXPBb45UW0GQR1XS
MHH-PREB-1 M1LQU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTN{LkS0JI5O MnHQV2FPT0WU
A101D M3;ROGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTtd3hKSzVyPUOyMlYzKG6P MXTTRW5ITVJ?
NMC-G1 NH3sTJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTN|Lk[3JI5O NEewOnBUSU6JRWK=
LB1047-RCC MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULUWHRTUUN3ME2zOE43QSCwTR?= NVHTT5JCW0GQR1XS
EM-2 NYLQUXVMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\1TWM2OD1|OD61N{BvVQ>? MoLyV2FPT0WU
COLO-684 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljwTWM2OD1|OT64JI5O NUPTVJJYW0GQR1XS
Becker NETCOmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfiN3VrUUN3ME20NU4xPSCwTR?= NF3GWZdUSU6JRWK=
BL-41 M2jPOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nlN2lEPTB;NEOuOlYhdk1? NWjEfmJ4W0GQR1XS
MDA-MB-134-VI M37JVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTR2LkCyJI5O NHri[YhUSU6JRWK=
L-363 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV65SVNUUUN3ME20OE44OyCwTR?= NUjxe4FFW0GQR1XS
ECC4 NGnsUG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTR2Lke4JI5O MVXTRW5ITVJ?
A388 MoPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTR2LkiyJI5O Mn7uV2FPT0WU
HEL MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPlTmJ2UUN3ME20PU44QSCwTR?= MYnTRW5ITVJ?
RKO M3jPeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;2bFlKSzVyPUWwMlI6KG6P MnHVV2FPT0WU
KINGS-1 NVPURY9xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHzXYNGUUN3ME21NU42PSCwTR?= M2e4OnNCVkeHUh?=
EB-3 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTV{Lk[3JI5O MorTV2FPT0WU
ARH-77 M1rYbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUH4UnJ[UUN3ME21Nk45KG6P NG\YR3NUSU6JRWK=
GCIY MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2T2fmlEPTB;NUOuOFYhdk1? MofQV2FPT0WU
NCI-H1304 M1XFV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17mRmlEPTB;NUeuNlIhdk1? NUfmfmVqW0GQR1XS
KARPAS-299 M3jTd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIC0eVlKSzVyPU[xMlgzKG6P M2nIXHNCVkeHUh?=
IA-LM MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnoNWxKSzVyPU[4MlE{KG6P MWjTRW5ITVJ?
GI-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfK[455UUN3ME23NE4{QSCwTR?= NV7HNFA3W0GQR1XS
TE-11 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17XXGlEPTB;N{euNVchdk1? MUjTRW5ITVJ?
LS-411N NUWySFJXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3nodWlEPTB;N{euOVchdk1? MlHGV2FPT0WU
no-11 M4LOPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1T2bGlEPTB;OEOuNlQhdk1? NED5WYdUSU6JRWK=
MV-4-11 Mn7WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnWTWM2OD16Mz63N{BvVQ>? NUDuWGg5W0GQR1XS
BV-173 Mk[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTh|Lkm3JI5O M1nTfHNCVkeHUh?=
CMK M{HEZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfUbWVKSzVyPUi0MlE3KG6P NITDbZFUSU6JRWK=
LC4-1 M2nrTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HzUWlEPTB;OE[uO|Ihdk1? MUnTRW5ITVJ?
COR-L279 NGS5eYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPoUGJ[UUN3ME24O{4zPSCwTR?= MnzYV2FPT0WU
NCI-H209 NI[yOVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWGzV5JbUUN3ME24O{41OSCwTR?= NGXF[XNUSU6JRWK=
Raji NIfvOYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXReFNKSzVyPUi5MlczKG6P Mnu1V2FPT0WU
LB996-RCC MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELLb4NKSzVyPUmzMlQ{KG6P M17POHNCVkeHUh?=
NCI-H526 M1THZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTl|LkW5JI5O NGLCTZBUSU6JRWK=
KGN M1\pdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHuVldXUUN3ME25Ok4zQSCwTR?= NUG2R2liW0GQR1XS
MOLT-4 NGnhW4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zDV2lEPTB;OU[uO|khdk1? M2rOTHNCVkeHUh?=
PF-382 M13Be2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jOU2lEPTB;OU[uO|khdk1? MoXTV2FPT0WU
BC-3 NUjibYVZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml6xTWM2OD17OT6xPEBvVQ>? MmnaV2FPT0WU
KARPAS-422 M{DyTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDjVlVKSzVyPUGwNk4xQSCwTR?= M3nNTHNCVkeHUh?=
SBC-1 MlzqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTFyNz63OUBvVQ>? NUS2[G9WW0GQR1XS
LC-1F M3rNPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PpZmlEPTB;MUC4MlA2KG6P NWrncnU6W0GQR1XS
GB-1 M3XnUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlP4TWM2OD1zMEmuNFIhdk1? Mly0V2FPT0WU
SNB75 NHqyPYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEi5UWFKSzVyPUGxPU43QSCwTR?= NFfNUHFUSU6JRWK=
BB65-RCC NFm2bYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrZdpNqUUN3ME2xNVkvQTNibl2= MVHTRW5ITVJ?
NCI-N87 M1;HfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmH0TWM2OD1zMkGuPVghdk1? NVrWeIhmW0GQR1XS
IST-MEL1 NFPIUIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NImzV2pKSzVyPUGyNk4{QCCwTR?= MkjmV2FPT0WU
HOP-62 M{GyVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLVTGNKSzVyPUGyOk45QSCwTR?= NWDuNIJWW0GQR1XS
ACN NGLkb3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jKbGlEPTB;MUS2Mlc2KG6P MW\TRW5ITVJ?
DMS-114 MorTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4i0TmlEPTB;MUWwMlY4KG6P MYHTRW5ITVJ?
MLMA NVnXd5ZHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPoTWM2OD1zNUmuPFghdk1? NU\Qb3FpW0GQR1XS
HT-144 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUL4S4xtUUN3ME2xOlUvPDNibl2= MYfTRW5ITVJ?
C2BBe1 MnrkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrQc2hKSzVyPUG2O{44PiCwTR?= NFjrfWJUSU6JRWK=
L-428 NWLaVlZyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTlNWkxUUN3ME2xO|cvPyCwTR?= MVvTRW5ITVJ?
DU-4475 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\XXJNKSzVyPUG4O{43QCCwTR?= NWjVVGxwW0GQR1XS
CP67-MEL Mn;NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTF7OT6zPEBvVQ>? NXixcXZ7W0GQR1XS
MEG-01 M3\u[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTJyMT65OkBvVQ>? M2Lqe3NCVkeHUh?=
IST-SL2 M1GyRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzlWFNKSzVyPUKwPE43OyCwTR?= M2XzOnNCVkeHUh?=
ES8 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HkWWlEPTB;MkK1Mlk1KG6P M4KwPXNCVkeHUh?=
COLO-800 NWjoUFJCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nMemlEPTB;MkO1MlI5KG6P NF3mTGRUSU6JRWK=
MFH-ino M{P0OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTJ|NT64OEBvVQ>? Mn:wV2FPT0WU
OVCAR-4 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGflWJBKSzVyPUKzO{4zPCCwTR?= M{f5e3NCVkeHUh?=
PSN1 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXOxPWgyUUN3ME2yOFIvPzFibl2= MVnTRW5ITVJ?
EW-12 NF7nWW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIniV2lKSzVyPUK0N{4yKG6P NWrkd4JZW0GQR1XS
HCC1599 M1zFfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTTd5lSUUN3ME2yOlEvPDdibl2= MX;TRW5ITVJ?
SJSA-1 NGPkW|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nHO2lEPTB;MkexMlQ3KG6P NFjIVZZUSU6JRWK=
ST486 MnP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4Lz[GlEPTB;Mkm2MlE1KG6P MXLTRW5ITVJ?
NOMO-1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEP3UI9KSzVyPUOwNE4zOSCwTR?= NVHacVdiW0GQR1XS
MN-60 NXTpNmduT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXZTWM2OD1|MEWuN|Ihdk1? NF;hTJpUSU6JRWK=
HCC1187 NVvMRo1xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfnWYlEUUN3ME2zNFcvOjVibl2= NGL3d|VUSU6JRWK=
SW982 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTNzND63OUBvVQ>? M1;IPHNCVkeHUh?=
LB647-SCLC M2PnRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrVXYU4UUN3ME2zNlgvPzFibl2= NUPXe5RiW0GQR1XS
HC-1 NUO0[FFXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvZTWM2OD1|M{WuOUBvVQ>? MVzTRW5ITVJ?
EHEB MkXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37oVWlEPTB;M{O3MlUzKG6P Mk\oV2FPT0WU
TUR MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4T3PWlEPTB;M{[zMlk2KG6P MX;TRW5ITVJ?
LU-139 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGWwR4ZKSzVyPUO3PE4xOiCwTR?= M1vNeXNCVkeHUh?=
NB1 NETC[pZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrxZ3NQUUN3ME2zPFQvPDVibl2= NYXNdJNmW0GQR1XS
BB30-HNC MmXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jneWlEPTB;M{i4MlMzKG6P M1nDcHNCVkeHUh?=
HAL-01 NVLUWJR7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3UTWM2OD1|OEmuNlYhdk1? NEO4[IxUSU6JRWK=
K5 MoLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTNTWM2OD12MUGuN|chdk1? NX3zNYp7W0GQR1XS
MZ2-MEL M3X4bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{[weGlEPTB;NEGzMlY1KG6P NGnqW2dUSU6JRWK=
RXF393 Mn7WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorwTWM2OD12MU[uOFUhdk1? NW[yT|QyW0GQR1XS
NCI-H1648 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDTU5A6UUN3ME20NVcvPTNibl2= M3nWcXNCVkeHUh?=
TE-12 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPkTWM2OD12M{SuNlYhdk1? M4jhcHNCVkeHUh?=
EoL-1- NEP4UJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHBUmxKSzVyPUSzO{46QCCwTR?= M{\RVHNCVkeHUh?=
JAR NEOySHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTR|OD62NkBvVQ>? MoTUV2FPT0WU
DSH1 Mn\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\4NGdUUUN3ME20OVgvQTFibl2= MVLTRW5ITVJ?
NCI-H187 M{LPe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHHcVhKSzVyPUS2Nk45OSCwTR?= MVfTRW5ITVJ?
HCE-4 M2CzW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXS5eYROUUN3ME20O|cvPjZibl2= MYLTRW5ITVJ?
8-MG-BA NIXiWYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTV6MT61NkBvVQ>? NH\yflBUSU6JRWK=
KLE NYDDOI9IT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjwSHJKSzVyPUW4OU4zKG6P M3PMfnNCVkeHUh?=
KNS-42 M1nTSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DHW2lEPTB;NUi2MlgyKG6P M2PZT3NCVkeHUh?=
MSTO-211H MmXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHn1WmJKSzVyPU[wPU44PCCwTR?= M4LldXNCVkeHUh?=
GDM-1 NVLQb2dXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPPOpFKSzVyPU[xOE4xQSCwTR?= M3\uVXNCVkeHUh?=
TE-1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;seWlEPTB;NkS2MlEzKG6P MUHTRW5ITVJ?
BT-474 MofJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjtTWM2OD14NEeuNFYhdk1? NYTGS5JsW0GQR1XS
KARPAS-45 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTZ2Nz62JI5O MYHTRW5ITVJ?
MOLT-16 NH\vUGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\Rd45KSzVyPU[0O{46OyCwTR?= M3TS[HNCVkeHUh?=
KURAMOCHI MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrheIlkUUN3ME22OVcvPTFibl2= M{C5e3NCVkeHUh?=
K-562 NH\PPGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInYT3pKSzVyPU[2PU42OSCwTR?= M3HPZ3NCVkeHUh?=
EKVX NFfqN5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVK0dZU2UUN3ME22O|IvPzFibl2= NX3FeFB4W0GQR1XS
GAK MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7ublFqUUN3ME22O|UvOyCwTR?= M1fSb3NCVkeHUh?=
NCI-SNU-5 NXny[IdmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYWwVW5zUUN3ME22PVAvODFibl2= M3nVOnNCVkeHUh?=
NCI-H2126 NULEd2plT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrjTWM2OD15Mk[uPFchdk1? NF;CWFRUSU6JRWK=
CTV-1 M4Xxd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDvTWM2OD15NESuPUBvVQ>? MYfTRW5ITVJ?
SW962 MlHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\PbnVKSzVyPUe0PE41PCCwTR?= Mn;SV2FPT0WU
MONO-MAC-6 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnBTWM2OD15NU[uPVMhdk1? MV7TRW5ITVJ?
NCI-H748 NIHiXIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTd3OD65PUBvVQ>? NXnpXYpnW0GQR1XS
NCI-H524 MonBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTd6MD63N{BvVQ>? MlrmV2FPT0WU
LS-123 MnS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrQTWM2OD15OUWuOlkhdk1? NY[3Spl5W0GQR1XS
NB7 NH;hO2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XufWlEPTB;OEG0MlE1KG6P MmXOV2FPT0WU
LS-1034 M3\UU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\vTWM2OD16MkiuPVghdk1? MoDzV2FPT0WU
TE-5 M3TLPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnobZlKSzVyPUi4N{42PiCwTR?= NFjpU41USU6JRWK=
A704 MlvkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\KWY1KSzVyPUi5PU4yPSCwTR?= M1\yVXNCVkeHUh?=
TK10 NH\YWIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITa[5pKSzVyPUmxOk4xOyCwTR?= NVnad3dxW0GQR1XS
NCI-H345 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXWb2xKSzVyPUm0N{4zOiCwTR?= MX3TRW5ITVJ?
CGTH-W-1 MljtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnL1TWM2OD17NEiuNVMhdk1? MVzTRW5ITVJ?
NCI-H510A M3vm[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rF[WlEPTB;OUi1MlEzKG6P MYDTRW5ITVJ?
NCI-H1963 NX7DXo5{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jGfGlEPTB;MT6wN|I6OiEQvF2= MnvtV2FPT0WU
SCC-3 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{H6OmlEPTB;MT6wN|QyPCEQvF2= NH\pNHRUSU6JRWK=
EW-11 MkjFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXDZ2lKSzVyPUGuNFg4PDNizszN NF70XmxUSU6JRWK=
CPC-N NH7sUpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzxTWM2OD1zLkC4PEDPxE1? M3H5N3NCVkeHUh?=
NCI-H1417 Ml3IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;ibpZkUUN3ME2xMlEzOjZizszN MU\TRW5ITVJ?
DG-75 M{\jXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\tTWM2OD1zLkG2Nlg2KM7:TR?= MmrjV2FPT0WU
HD-MY-Z MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfn[VZKSzVyPUGuNVY1OTZizszN NV:2OZI1W0GQR1XS
ATN-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PSOWlEPTB;MT6yOlIxQSEQvF2= NGSyUoRUSU6JRWK=
KM-H2 NYrRVXp{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXxW4FKSzVyPUGuNlY1ODhizszN MnP6V2FPT0WU
NCI-H2081 M4rNOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTFwMk[2N|ch|ryP MmDzV2FPT0WU
HL-60 NVnhZnRET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXMcXZKSzVyPUGuNlY6PTlizszN NE\oVmFUSU6JRWK=
DB NG\3emFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTFwMkeyOFIh|ryP MXjTRW5ITVJ?
NCI-H1522 NI[wPYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3GOVhEUUN3ME2xMlI5QDh5IN88US=> MV3TRW5ITVJ?
AM-38 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFv5T3BKSzVyPUGuN|A4OiEQvF2= MWnTRW5ITVJ?
NCI-H446 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTFwM{KxNlEh|ryP NWnVOmFzW0GQR1XS
SU-DHL-1 NFriXXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mny1TWM2OD1zLkOyPFAyKM7:TR?= NEfMWFJUSU6JRWK=
NH-12 NUn4TZVsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLHR40xUUN3ME2xMlM3Ozd2IN88US=> NGHZXpFUSU6JRWK=
DMS-79 NGDQTJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTNXnVKSzVyPUGuN|Y5PjZizszN MWnTRW5ITVJ?
NCI-H716 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHT[XR4UUN3ME2xMlM5QTh4IN88US=> NHKxboRUSU6JRWK=
ML-2 M{PNUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\FTWM2OD1zLkSxOVI6KM7:TR?= NWfEem0zW0GQR1XS
NB10 M3e0[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\jZm8xUUN3ME2xMlQ3PjN{IN88US=> Mo\NV2FPT0WU
ONS-76 M3HoZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\XN2tsUUN3ME2xMlU{PTZ7IN88US=> NGnjRmJUSU6JRWK=
LOUCY NVrme3V7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHmeGh{UUN3ME2xMlU1PjV5IN88US=> MVzTRW5ITVJ?
SCLC-21H NVvC[mFtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU[wU2IxUUN3ME2xMlU5PTh{IN88US=> NIq5ZW1USU6JRWK=
TGW NH3mNJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jwfWlEPTB;MT62N|k4PSEQvF2= M{DBNHNCVkeHUh?=
LXF-289 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13qUWlEPTB;MT63N|I3QCEQvF2= NXG1[YdWW0GQR1XS
BB49-HNC Mm\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPGZlk4UUN3ME2xMlc{PTh4IN88US=> NHzjXJJUSU6JRWK=
NCI-H747 NXvJOZNlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPLZ4g5UUN3ME2xMlc2OzR4IN88US=> MoS2V2FPT0WU
LU-165 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTFwOES5PFYh|ryP M1;rc3NCVkeHUh?=
OMC-1 NIHwU5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjObHhMUUN3ME2xMlk2ODZ4IN88US=> M1zpdnNCVkeHUh?=
RCC10RGB M{LyS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTFwOUW4NVch|ryP MoT1V2FPT0WU
SW684 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fQOWlEPTB;MT65OlA6QSEQvF2= M{O2dXNCVkeHUh?=
TE-8 NWC4Z2sxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHLSGpRUUN3ME2yMlA2PTV7IN88US=> NVy5WnJlW0GQR1XS
SK-N-DZ MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3nFZmlEPTB;Mj6xN|I4PCEQvF2= NFXHNZdUSU6JRWK=
EVSA-T MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTJwMUezNVUh|ryP NFrQfllUSU6JRWK=
KASUMI-1 M3TDWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHGWHNKSzVyPUKuNVg5OTVizszN NVH2O3lNW0GQR1XS
NKM-1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrITWM2OD1{LkK1OFczKM7:TR?= NF7JTYJUSU6JRWK=
CAL-148 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\VTWM2OD1{LkOzOlE1KM7:TR?= MUHTRW5ITVJ?
NCI-H64 M4LUPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTJwM{SyN|Ih|ryP NUjTTpRNW0GQR1XS
KNS-81-FD NEOxSIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjnVodKSzVyPUKuN|Y3OiEQvF2= NFzldJVUSU6JRWK=
KM12 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHPTWM2OD1{LkSwPFM6KM7:TR?= NVy5Z2ZFW0GQR1XS
SW954 MkfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoflTWM2OD1{LkS3O|c6KM7:TR?= M2e2PXNCVkeHUh?=
NCI-H1395 M3qwWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{D5eWlEPTB;Mj61NlY1PSEQvF2= MV7TRW5ITVJ?
DJM-1 M3zJU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{O1UGlEPTB;Mj62NFY{KM7:TR?= M1TFVHNCVkeHUh?=
COLO-668 MlnMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnjTItpUUN3ME2yMlgzPjl3IN88US=> NHzVNoVUSU6JRWK=
NCI-H1436 MlrRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUD3bZFZUUN3ME2yMlg2PjF3IN88US=> NIDCW4pUSU6JRWK=
LB2241-RCC MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7CTWM2OD1{Lki2PFM6KM7:TR?= NIPPO5dUSU6JRWK=
GT3TKB NH\WOYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1i2e2lEPTB;Mj64PVA2PSEQvF2= NUTufHd6W0GQR1XS
COLO-824 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XtemlEPTB;Mj64PVc3QCEQvF2= NIewbW9USU6JRWK=
ES1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3OxV2lEPTB;Mj64PVg4QSEQvF2= M2XQXHNCVkeHUh?=
LB771-HNC M2jMOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17QfGlEPTB;Mj65NFk1PiEQvF2= NGLjem9USU6JRWK=
GI-ME-N NVv0dmhpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTNwMEC5NFQh|ryP M2PrbHNCVkeHUh?=
NALM-6 M1T1Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYSwR3B1UUN3ME2zMlAxQTN|IN88US=> NF\6fGtUSU6JRWK=
LU-134-A Ml\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDtbmVFUUN3ME2zMlA2PDJ3IN88US=> M1\mUnNCVkeHUh?=
DMS-153 NXfSZYtyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTNwMEW4NlQh|ryP NHTZe5ZUSU6JRWK=
MZ1-PC MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NES4SYVKSzVyPUOuNFkxPzhizszN MV\TRW5ITVJ?
NCI-H1155 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnhOY5JUUN3ME2zMlEyPjFizszN M1rKTnNCVkeHUh?=
CAS-1 Mn;JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUf3cGFkUUN3ME2zMlE{PzB5IN88US=> NH\1UYNUSU6JRWK=
D-502MG NGDnNJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\MTWM2OD1|LkG0N|kh|ryP MVTTRW5ITVJ?
NCI-H2141 M4T3WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTNwMUe0OVIh|ryP MkfBV2FPT0WU
NB6 NFKxOVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PZdWlEPTB;Mz6xPFI2QSEQvF2= Mle4V2FPT0WU
NCCIT NUHlNXNXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWX2cVJvUUN3ME2zMlIyQDB7IN88US=> M2\TWXNCVkeHUh?=
NB69 MmnvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjsVmJtUUN3ME2zMlMyQDlzIN88US=> NV\p[lhlW0GQR1XS
JVM-2 Mn;2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTNwM{[0N|Mh|ryP M2H4WHNCVkeHUh?=
K052 M4KyPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUP0NldCUUN3ME2zMlM4QTZ6IN88US=> NGHWfJRUSU6JRWK=
HCC2157 NIf1WWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHFNnFGUUN3ME2zMlU{OjJ6IN88US=> NEfQfo9USU6JRWK=
KMOE-2 NVv5V4NUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTNwNUSyOFIh|ryP NUXXdoxsW0GQR1XS
SF268 NWftfnNET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MliyTWM2OD1|LkexOVU1KM7:TR?= MkWxV2FPT0WU
CHP-126 NHfUfHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\ITWM2OD1|Lke2OFU5KM7:TR?= NV\ucIZHW0GQR1XS
CP66-MEL MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF6zO3pKSzVyPUOuO|kxQTRizszN MXTTRW5ITVJ?
NCI-H69 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrVbJBKSzVyPUSuNFE6OzZizszN M4Py[XNCVkeHUh?=
A253 NVj5c5N5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVH4PI51UUN3ME20MlAzOTBzIN88US=> MoTYV2FPT0WU
NB14 M2rrcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTRwMUC0O|kh|ryP MXLTRW5ITVJ?
NCI-H1694 Mo\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vVNWlEPTB;ND6xN|EyOiEQvF2= NFXO[WVUSU6JRWK=
NCI-H2196 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fhVWlEPTB;ND6xO|E3QSEQvF2= NXjIRpQ2W0GQR1XS
TE-9 MnzsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDKWVFKSzVyPUSuNVc2QDJizszN NXv5TGxxW0GQR1XS
D-283MED M175fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInhSFlKSzVyPUSuNVg5PCEQvF2= M3j4RnNCVkeHUh?=
OCI-AML2 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4j5d2lEPTB;ND6xPVQ5QSEQvF2= MVnTRW5ITVJ?
D-263MG MlexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;EO4ZKSzVyPUSuNlI6PjFizszN NV\pcWgxW0GQR1XS
MPP-89 NF;oUGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTRwMkezNFQh|ryP NEjl[4ZUSU6JRWK=
LAMA-84 MmX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTRwM{C0NlEh|ryP MYTTRW5ITVJ?
LB373-MEL-D NHPHc4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jZXmlEPTB;ND6zOlc5QSEQvF2= NF3o[FBUSU6JRWK=
UACC-257 M{XN[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFu0U4FKSzVyPUSuN|k2OzRizszN Mn;hV2FPT0WU
MC-CAR M4HUTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDic5RrUUN3ME20MlQ{QTlizszN MXTTRW5ITVJ?
COLO-320-HSR MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjCcVNzUUN3ME20MlQ1PDJ5IN88US=> MXnTRW5ITVJ?
P30-OHK NX;EN3dJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjkTWM2OD12Lk[2OVgyKM7:TR?= NXzUPYJpW0GQR1XS
UACC-812 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HIdmlEPTB;ND62PVE3OSEQvF2= NH35TlFUSU6JRWK=
CTB-1 NEfjSXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIS2cYRKSzVyPUSuO|E2PTVizszN NF;1R4RUSU6JRWK=
ALL-PO M320[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTRwOESwO|ch|ryP MXHTRW5ITVJ?
SK-MEL-2 NW\LfXpRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInUV5FKSzVyPUSuPFY6PTVizszN NEKxdoJUSU6JRWK=
TC-YIK NFzt[3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHznWIlKSzVyPUSuPVc6PDJizszN NH30cnZUSU6JRWK=
NCI-H1882 NYPG[W0{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7UU5lzUUN3ME21MlAzODBzIN88US=> M3K3VnNCVkeHUh?=
MHH-CALL-2 NG\VRnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrsWXlKSzVyPUWuNFUxPDJizszN MWfTRW5ITVJ?
U-87-MG M4LTWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3yXGlHUUN3ME21MlA6PDZ4IN88US=> MofzV2FPT0WU
NCI-H1092 NVP1U3FST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXpTWM2OD13LkK2OVU2KM7:TR?= NX\lXolpW0GQR1XS
TE-441-T NHniTpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTDOGNRUUN3ME21MlI4QDJizszN MXjTRW5ITVJ?
SK-MEL-1 Mlu4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTVwMkmwOFQh|ryP NHnsSXJUSU6JRWK=
EW-22 M4HH[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1Ls[WlEPTB;NT6yPVQ3PiEQvF2= M4TVNHNCVkeHUh?=
MZ7-mel NUXBZXF6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2r1VWlEPTB;NT60NFY6OSEQvF2= NYfzem55W0GQR1XS
LP-1 MojLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlu5TWM2OD13LkSxNlkyKM7:TR?= M3XBXnNCVkeHUh?=
NCI-SNU-16 MnzkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTVwNkSwO|Qh|ryP M2[zOnNCVkeHUh?=
LU-65 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnIdYtKSzVyPUWuO|Y{PzNizszN MYrTRW5ITVJ?
CW-2 NV3ZZnc{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTVwOEW5OVkh|ryP MWrTRW5ITVJ?
WSU-NHL MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH35eZBKSzVyPUWuPVUyPzRizszN MUTTRW5ITVJ?
IST-MES1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrJTWM2OD13Lkm1OFQ{KM7:TR?= M4jiZXNCVkeHUh?=
U-266 M3zEWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTVwOUiyNFIh|ryP NUnjbJM5W0GQR1XS
TALL-1 MnTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmGxTWM2OD14LkG0Olg5KM7:TR?= M3:zOnNCVkeHUh?=
Calu-6 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mkm4TWM2OD14LkG1N|E3KM7:TR?= MVHTRW5ITVJ?
MMAC-SF M4fybmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjDTWM2OD14LkG4OVU3KM7:TR?= MULTRW5ITVJ?
NCI-H82 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTZwMkC0PFkh|ryP NF;NS5NUSU6JRWK=
RS4-11 NFTPVG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGKxPGlKSzVyPU[uNlU5QTdizszN NVW2boZ1W0GQR1XS
SNU-C2B NVPQbW9ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorOTWM2OD14LkSwPVY6KM7:TR?= MkLEV2FPT0WU
BOKU NIjFd3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTZwNEe1PVch|ryP MWPTRW5ITVJ?
C8166 MkLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fHZmlEPTB;Nj61OVkyOiEQvF2= MYPTRW5ITVJ?
D-247MG NVvGZVNkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHNb|NKSzVyPUeuNFQ{PDdizszN NULke5lWW0GQR1XS
EW-18 NXe3dFByT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTdwMEeyPVIh|ryP NVrKXXJFW0GQR1XS
KG-1 NV\KeFZHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTdwNkK3N|gh|ryP M3W3dnNCVkeHUh?=
REH MlvzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnIN4dDUUN3ME23MlY5OTB7IN88US=> M3XxXnNCVkeHUh?=
U-698-M M4XCTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTdwOESzNVUh|ryP Mn;SV2FPT0WU
KP-N-RT-BM-1 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHz1SnpKSzVyPUeuPVMxOjlizszN MV3TRW5ITVJ?
MS-1 NUm5N2h6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVziRYZtUUN3ME23Mlk3ODRzIN88US=> NH3HcoRUSU6JRWK=
SNU-C1 NXfhVFEyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTdwOUixPVIh|ryP M4r3e3NCVkeHUh?=
SK-MM-2 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\VSnV[UUN3ME24MlI3ODZ3IN88US=> M2mwOHNCVkeHUh?=
LAN-6 M1H3c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrkOZZKSzVyPUiuN|AxODFizszN NVfIdW1jW0GQR1XS
NEC8 NIrYPYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRThwM{C2PVEh|ryP NXfDWm9YW0GQR1XS
NCI-H1770 MmX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoS3TWM2OD16LkO4NFAzKM7:TR?= MUDTRW5ITVJ?
D-336MG MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRThwNECxNVYh|ryP NIK0[nhUSU6JRWK=
COLO-829 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXrTWM2OD16LkS4PFc6KM7:TR?= MnfjV2FPT0WU
LS-513 Mn64S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRThwNUm1PVkh|ryP NYGxOXczW0GQR1XS
YT NITwWppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPET4lKSzVyPUiuOlI1OjdizszN NVfk[HZYW0GQR1XS
EW-24 M33EXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3a[ldKSzVyPUiuO|Y2PCEQvF2= MnvwV2FPT0WU
IST-SL1 M1raVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRThwOE[1OFMh|ryP NUCwdVAzW0GQR1XS
CA46 NGPhblJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7INWlKSzVyPUiuPVUxQThizszN M1jJTHNCVkeHUh?=
NCI-H1838 Mn7IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRThwOUi2NFIh|ryP Mk\VV2FPT0WU
NCI-H719 NH[5[m1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrafFc3UUN3ME25MlI2Ojd7IN88US=> M{TER3NCVkeHUh?=
HCE-T NFHnNFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvKNmVKSzVyPUmuN|A5PTFizszN M2KxfXNCVkeHUh?=
A498 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTlwM{[xNlQh|ryP NUnV[lhSW0GQR1XS
LB831-BLC MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\1WHBQUUN3ME25Mlc3PTJzIN88US=> MXnTRW5ITVJ?
SKM-1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkD1TWM2OD17Lki1PVY{KM7:TR?= NVTjc5ROW0GQR1XS
THP-1 NHLCU4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPVTWM2OD17Lkm2PVE5KM7:TR?= MkXTV2FPT0WU
SHP-77 Mn[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTFyLkSwO{DPxE1? MnnBV2FPT0WU
EW-3 NYTmWol1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLKbXMzUUN3ME2xNE43Ojh7IN88US=> NXrVeW5[W0GQR1XS
KY821 NFj0bYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfvPYJKSzVyPUGwMlc3OyEQvF2= NFzCSotUSU6JRWK=
NCI-SNU-1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTFzLkCyNVch|ryP MVfTRW5ITVJ?
HCC2218 M3rOTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHviWWNKSzVyPUGxMlM6QDZizszN MmfnV2FPT0WU
IM-9 NUXYRlJlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITYR3dKSzVyPUGxMlUyODZizszN M2GxUHNCVkeHUh?=
NCI-H889 M2j0VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnL3TWM2OD1zMT61N|E{KM7:TR?= M136bHNCVkeHUh?=
HDLM-2 NV24[HJXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjOb|IyUUN3ME2xNk41OTV7IN88US=> NESzfpFUSU6JRWK=
LB2518-MEL NVXYUW05T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWWxclhCUUN3ME2xNk43QDF3IN88US=> M4DHRXNCVkeHUh?=
NCI-H23 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVzqdYJLUUN3ME2xN{4zPDJ3IN88US=> NIrPUndUSU6JRWK=
NB17 NEX2SmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnnV4RLUUN3ME2xN{41PTd7IN88US=> MlzsV2FPT0WU
NCI-H322M NYHLPYVZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnSc2dFUUN3ME2xOE41ODZ6IN88US=> M3;wRnNCVkeHUh?=
SUP-T1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rGc2lEPTB;MUSuOFE{KM7:TR?= MXjTRW5ITVJ?
ES3 M1fY[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTF3LkC3NFMh|ryP M2PKZXNCVkeHUh?=
ES5 NXHCToxYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MliyTWM2OD1zNT6wO|g4KM7:TR?= MYXTRW5ITVJ?
NCI-H1650 NYqw[5hjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjnTWM2OD1zNT60PVc6KM7:TR?= M1LFXnNCVkeHUh?=
NCI-H226 NGS3WmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlq2TWM2OD1zNT64O|Y5KM7:TR?= M2fidHNCVkeHUh?=
COR-L88 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTF4LkOxOEDPxE1? NVPhXJNmW0GQR1XS
SCC-15 Mnq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DWXWlEPTB;MU[uN|g3QSEQvF2= MY\TRW5ITVJ?
GOTO M1XMOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTJU4xKSzVyPUG2MlQ4QTNizszN MVvTRW5ITVJ?
SIMA MlnnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{Xq[WlEPTB;MU[uOFgxOiEQvF2= M1jLOXNCVkeHUh?=
NCI-H1299 Mnm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorBTWM2OD1zNz6xOVkyKM7:TR?= M2jWW3NCVkeHUh?=
NCI-H1581 NE\yVlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HkTWlEPTB;MUeuOFIyQSEQvF2= M2K2dnNCVkeHUh?=
MHH-NB-11 M4jK[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLkNnd{UUN3ME2xO{46Pjh|IN88US=> MkTtV2FPT0WU
MFM-223 M{PrN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7ifFBoUUN3ME2xPE4xPTN6IN88US=> NYTrT2VjW0GQR1XS
ES7 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HtTWlEPTB;MUiuOVQ{OSEQvF2= M1flTXNCVkeHUh?=
JVM-3 M13lOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2G2RmlEPTB;MUiuO|E4KM7:TR?= M{Xn[HNCVkeHUh?=
RL MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LPR2lEPTB;MkCuN|g5KM7:TR?= MmnXV2FPT0WU
EC-GI-10 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\iTWM2OD1{MT6yNFQyKM7:TR?= NXnDSI5OW0GQR1XS
LNCaP-Clone-FGC NWXlPFJ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTJzLk[3Olgh|ryP NFGxflNUSU6JRWK=
IMR-5 Ml;vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW[3SHEyUUN3ME2yNU45PDl2IN88US=> MX\TRW5ITVJ?
KP-N-YS M3HzUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTxTWM2OD1{MT64O|Uh|ryP MkT4V2FPT0WU
Mo-T MlvtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HNfGlEPTB;MkKuNlE5PSEQvF2= NFzlNphUSU6JRWK=
NCI-H128 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPDTWM2OD1{Mz61PFU{KM7:TR?= MlHRV2FPT0WU
RH-1 Mnq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrTeItKSzVyPUKzMlc5PjZizszN NGHYUY1USU6JRWK=
NCI-H2171 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTJ2LkK0PFUh|ryP Mn3SV2FPT0WU
RPMI-8866 M2P0Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHzqRnpKSzVyPUK2Mlc1OiEQvF2= NF\aNmpUSU6JRWK=
SK-N-FI NILLPHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorpTWM2OD1{Nz6zPFEyKM7:TR?= MnzwV2FPT0WU
LOXIMVI NFe4U2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HtUWlEPTB;MkeuPFA2OSEQvF2= NWn3UHVNW0GQR1XS
P31-FUJ M13LT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTmNnhSUUN3ME2zNU42Ozd2IN88US=> MnvWV2FPT0WU
KMS-12-PE NYjCboV2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnOS4NKSzVyPUS5MlU{ODJizszN M17DbnNCVkeHUh?=

... Click to View More Cell Line Experimental Data
Assay
Methods Test Index PMID
Western blot
p-mTOR(S2448)/mTOR; 

PubMed: 23991038     


MCF-7-vector and MCF-7-ZNF703 cells were treated with DMSO, 0.1 µM rapamycin, or 1 µM rapamycin for 24 hours before cell lysis. Western blot analysis of lysates using the indicated antibodies. A GAPDH antibody was used as a loading control.

23991038
Growth inhibition assay
Cell proliferation; 

PubMed: 30393233     


(A) Effect of Rapamycin treatment on SK-N-SH cell proliferation. (B) Effect of Rapamycin treatment on SH-SY5Y cell proliferation. Rapamycin, except treatment of 10 µM for 12 h, can obviously inhibited proliferation of NB cells compared with corresponding control group (P<0.05). (*) indicates statistically significant difference with P<0.05.

30393233
Histomorphology
Haematoxylin & Eosin; 

PubMed: 28418837     


Representative pictures of H&E-stained U87MG cells. The fusiform cell body observed in control cells A. disappears in cells exposed to increasing doses of rapamycin for 24 h B.-E. Rapamycin produces a dose-dependent increase in the diameter of the cell body which develops a pyramidal shape. 1 nM (B); 10 nM (C); 100 nM (D); 1 μM (E) of rapamycin exposure.

28418837
Immunofluorescence
NeuN; 

PubMed: 28418837     


Immune-fluorescence of U87MG cells treated with vehicle A.-D. and rapamycin at the dose of 10 nM E.-H.; 100 nM I.-L.; 1 μM M.-P. In the first line cells were stained for the late post-mitotic neuronal marker NeuN. In the second line cells were stained for the nuclear dye DAPI. In the third line the merging between NeuN (green) and DAPI (blue) fluorescence is shown. In the fourth line a high magnification of the squared insert of line three is shown.

p62/Beclin; 

PubMed: 28819214     


(C,D) Rapamycin treatment reduced the aggregate level of p62 and Beclin 1 in cardiomyocytes. NRVCs were transduced with Ad-Nef or Ad-null for 48 hours and cells were fixed with 4% PFA. Fixed cells were stained with p62 and Beclin 1 antibody. 

28418837 28819214
ELISA
Type III collagen/Fibronectin; 

PubMed: 23364979     


(A) Rapamycin inhibits TGF-β1-induced type III collagen level in the culture medium of human lung fibroblast, evidenced by ELISA. Type III collagen level after 24-h incubation with medium alone (control), 0.01, 0.1, 1.0, and 10 ng/mL rapamycin and 10 ng/mL TGF-β1. No significant difference was found between different concentration groups of rapamycin. (B) Rapamycin inhibits TGF-β1-induced fibronectin level in the culture medium of human lung fibroblast, shown by ELISA. Fibronectin level after 24-h incubation with medium alone (control), 0.01, 0.1, 1.0, and 10 ng/mL rapamycin and 10 ng/mL TGF-β1. Values are mean of three independent experiments. No significant difference was found between different concentration groups of rapamycin. *p<0.05 vs. control; †p<0.05 vs. TGF-β1 group. TGF-β1, transforming growth factor β1.

23364979
In vivo Treatment with Rapamycin in vivo specifically blocks targets known to be downstream of mTOR such as the phosphorylation and activation of p70S6K and the release of inhibition of eIF4E by PHAS-1/4E-BP1, leading to complete blockage of the hypertrophic increases in plantaris muscle weight and fibre size. [4] Short-term Rapamycin treatment, even at the lowest dose of 0.16 mg/kg, produces profound inhibition of p70S6K activity, which correlates with increased tumor cell death and necrosis of the Eker renal tumors. [5] Rapamycin inhibits metastatic tumor growth and angiogenesis in CT-26 xenograft models by reducing the production of VEGF and blockage of VEGF-induced endothelial cell signaling. [6] Rapamycin treatment at 4 mg/kg/day significantly reduces tumor growth of C6 xenografts, and tumor vascular permeability. [7]

Protocol

Kinase Assay:

[1]
- Collapse

Immunoblotting for the mTOR kinase assay:

HEK293 cells are plated at 2-2.5×105 cells/well of a 12-well plate and serum-starved for 24 hours in DMEM. Cells are treated with increasing concentrations of Rapamycin (0.05-50 nM) for 15 minutes at 37 °C. Serum is added to a final concentration of 20% for 30 minutes at 37 °C. Cells are lysed, and cell lysates are separated by SDS-PAGE. Resolved proteins are transferred to a polyvinylidene difluoride membrane and immunoblotted with a phosphospecific primary antibody against Thr-389 of p70 S6 kinase. Data are analyzed using ImageQuant and KaleidaGr
Cell Research:

[3]
- Collapse
  • Cell lines: U87-MG, T98G, and U373-MG
  • Concentrations: Dissolved in DMSO, final concentrations ~25 μM
  • Incubation Time: 72 hours
  • Method:

    Cells are exposed to various concentrations of Rapamycin for 72 hours. For the assessment of cell viability, cells are collected by trypsinization, stained with trypan blue, and the viable cells in each well are counted. For the determination of cell cycle, cells are trypsinized, fixed with 70% ethanol, and stained with propidium iodide using a flow cytometry reagent set. Samples are analyzed for DNA content using a FACScan flow cytometer and CellQuest software. For apoptosis detection, cells are stained with the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) technique using an ApopTag apoptosis detection kit. To detect the development of acidic vesicular organelles (AVO), cells are stained with acridine orange (1 μg/mL) for 15 minutes, and examined under a fluorescence microscope. To quantify the development of AVOs, cells are stained with acridine orange (1 μg/mL) for 15 minutes, removed from the plate with trypsin-EDTA, and analyzed using the FACScan flow cytometer and CellQuest software. To analyze the autophagic process, cells are incubated for 10 minutes with 0.05 mM monodansylcadaverine at 37 °C and are then observed under a fluorescence microscope.


    (Only for Reference)
Animal Research:

[7]
- Collapse
  • Animal Models: Athymic Nu/Nu mice inoculated subcutaneously with VEGF-A-expressing C6 rat glioma cells
  • Formulation: Dissolved in solvent solution (0.2% carboxymethylcellulose and 0.25% Tween-80 in sterile H2O)
  • Dosages: ~4 mg/kg/day
  • Administration: Injection i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 20 mg/mL (21.87 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing. 		5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 914.18
Formula

C51H79NO13
CAS No. 53123-88-9
Storage powder
in solvent
Synonyms AY 22989，NSC-2260804

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03433183 Recruiting Drug: Selumetinib|Drug: Sirolimus Malignant Peripheral Nerve Sheath Tumors|Neurofibromatosis 1 Sarcoma Alliance for Research through Collaboration|United States Department of Defense|AstraZeneca October 2 2019 Phase 2
NCT03933904 Recruiting Drug: Sirolimus Castleman Disease|Castleman''s Disease Multicentric University of Pennsylvania September 25 2019 Phase 2
NCT03972592 Recruiting Drug: Topical 0.1% Sirolimus|Drug: Topical Vehicle Vascular Malformations|Lymphatic Malformation University Hospital Tours|University Hospital Angers June 5 2019 Phase 2
NCT03811717 Completed Other: FAST+EX|Other: FAST Skeletal Muscle Energetics Queen''s University|University of Waterloo January 14 2019 Not Applicable
NCT03765944 Completed Drug: sirolimus Bioequivalence Study Nobelpharma December 5 2018 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field
selleck catalog

mTOR Signaling Pathway Map

mTOR Inhibitors with Unique Features

  • Pan mTOR inhibitor

    KU-0063794 : mTORC1 and mTORC2, IC50=~10 nM.

  • FDA-approved mTOR Inhibitor

    Temsirolimus (CCI-779, NSC 683864) : Approved by FDA for Renal Cell Carcinoma (RCC).

  • Newest mTOR Inhibitor

    XL388 New : Highly potent, selective, ATP-competitive inhibitor of mTOR with IC50 of 9.9 nM, 1000-fold selectivity over the closely related PI3K kinases.

  • Classic mTOR Inhibitor

    BEZ235 (NVP-BEZ235, Dactolisib) : Dual ATP-competitive PI3K and mTOR inhibitor for p110α/γ/δ/β and mTOR(p70S6K) with IC50 of 4 nM/5 nM/7 nM/75 nM/6 nM, respectively.

Related mTOR Products

  • MHY1485 New

    MHY1485 is a potent, and cell-permeable mTOR activator, and also potently inhibits autophagy.

  • CHIR-99021 (CT99021) New

    CHIR-99021 (CT99021) is a GSK-3α and GSK-3β inhibitor with IC50 of 10 nM and 6.7 nM, respectively. CHIR99201 does not exhibit cross-reactivity against cyclin-dependent kinases (CDKs) and shows a 350-fold selectivity toward GSK-3β compared to CDKs.

  • Dorsomorphin (Compound C) New

    Dorsomorphin is a potent, reversible, selective AMPK inhibitor with Ki of 109 nM in cell-free assays, exhibiting no significant inhibition of several structurally related kinases including ZAPK, SYK, PKCθ, PKA, and JAK3. Also inhibits type I BMP receptor activity.

  • Everolimus (RAD001)

    Everolimus (RAD001) is an mTOR inhibitor of FKBP12 with IC50 of 1.6-2.4 nM in a cell-free assay.

  • AZD8055

    AZD8055 is a novel ATP-competitive mTOR inhibitor with IC50 of 0.8 nM in MDA-MB-468 cells with excellent selectivity (∼1,000-fold) against PI3K isoforms and ATM/DNA-PK. Phase 1.

    Features:First drug to inhibit both types of mTOR protein.

  • Torin 1

    Torin 1 is a potent inhibitor of mTORC1/2 with IC50 of 2 nM/10 nM in cell-free assays; exhibits 1000-fold selectivity for mTOR than PI3K.

  • Temsirolimus (CCI-779, NSC 683864)

    Temsirolimus (CCI-779, NSC 683864) is a specific mTOR inhibitor with IC50 of 1.76 μM in a cell-free assay.

  • Sapanisertib (INK 128, MLN0128,TAK-228)

    Sapanisertib (INK 128, MLN0128) is a potent and selective mTOR inhibitor with IC50 of 1 nM in cell-free assays; >200-fold less potent to class I PI3K isoforms, superior in blocking mTORC1/2 and sensitive to pro-invasion genes (vs Rapamycin). Phase 1.

  • Tacrolimus (FK506)

    Tacrolimus (FK506) is a 23-membered macrolide lactone, it reduces peptidyl-prolyl isomerase activity in T cells by binding to the immunophilin FKBP12 (FK506 binding protein) creating a new complex.

  • KU-0063794

    KU-0063794 is a potent and highly specific dual-mTOR inhibitor of mTORC1 and mTORC2 with IC50 of ~10 nM in cell-free assays; no effect on PI3Ks.

Tags: buy Rapamycin (Sirolimus) | Rapamycin (Sirolimus) supplier | purchase Rapamycin (Sirolimus) | Rapamycin (Sirolimus) cost | Rapamycin (Sirolimus) manufacturer | order Rapamycin (Sirolimus) | Rapamycin (Sirolimus) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID